Hemacell Biotechnology

Hemacell Biotechnology is a clinical-stage-focused biotechnology company headquartered in Suzhou, China, specializing in the industrial-scale production of human blood cells using induced pluripotent stem cell (iPSC) technology. The company's primary focus is developing "universal" blood products, such as O-type red blood cells and platelets, which are designed to be off-the-shelf and compatible with all patients regardless of blood type. By creating a sustainable and standardized alternative to volunteer-based blood donation, Hemacell aims to address critical global shortages and eliminate risks associated with donor-derived pathogens. Their technological platform integrates advanced cell reprogramming, gene editing, and large-scale bioreactor expansion to deliver high-purity, clinical-grade hematopoietic products.